Alembic Gears For Derma Push With New JV
This article was originally published in Scrip
Shares of Alembic Pharmaceuticals spurted on Indian bourses on April 21 after the firm said that it had formed a joint venture with the privately held Orbicular Pharmaceutical Technologies and one of its founders, Dr MS Mohan, for dermatology products.
You may also be interested in...
Alembic Pharmaceuticals, which has seen a dazzling FY16, appears set to build on its strong showing in the US with plans for filings in the oncology and dermatology space and a potential ramp up of its own label products there.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.